Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response

NCT07670715 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Thoracic Radiotherapy
Immune Checkpoint Inhibitors
Neoadjuvant Chemoimmunotherapy

Interventions

RADIATION: lattice radiation therapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital